The maximum allowable cost paid for antihemophilic Factor VII, VIII, IX and X products under the Medicaid program shall be the actual acquisition cost as reflected on the manufacturer's invoice plus eight per cent plus the professional dispensing fee established for covered outpatient drugs.
(June Sp. Sess. P.A. 00-2, S. 35, 53; P.A. 04-76, S. 22; P.A. 11-44, S. 131; P.A. 13-234, S. 100; June Sp. Sess. P.A. 17-2, S. 200.)
History: June Sp. Sess. P.A. 00-2 effective July 1, 2000; P.A. 04-76 deleted reference to “general assistance”; P.A. 11-44 deleted “state-administered general assistance”, effective July 1, 2011; P.A. 13-234 deleted reference to ConnPACE program, effective January 1, 2014; June Sp. Sess. P.A. 17-2 deleted provision re Factor VIII pharmaceuticals, added “antihemophilic Factor VII, VIII, IX and X products”, added reference to manufacturer's invoice re acquisition cost and added “plus the professional dispensing fee established for covered outpatient drugs”, effective October 31, 2017.